Clinical trials: Inflammatory
Severe Infection, Sepsis
Evaluation of MDW for Early Detection of Sepsis, Clinical Validity
The purpose of this study is to confirm the clinical validity and the performance of the Monocyte Width Distribution (MDW) parameter to detect the development of sepsis in a prospective study of Emergency Department (ED) adults…
- Conditions
- Severe Infection, Sepsis, Severe Sepsis
- Trial name
- NCT03588325
- Testing
- CBC-DIFF with MDW, PCT, CRP
- Where
- 2 sites in France, Spain
- Volunteers
- 947 people
- Sponsor
- Beckman Coulter, Inc.
Respiratory Tract Infections, Urinary Tract Infections
TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis
This study will analyze gene expression and other laboratory data from biological samples collected from participants with suspected respiratory, urinary, intra-abdominal, and/or skin \& soft tissue infections; or suspected…
- Conditions
- Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection
- Trial name
- SEPSIS-SHIELD (NCT04094818)
- Testing
- TriVerity
- Where
- 26 sites in United States, Greece
- Volunteers
- 1,441 people
- Sponsor
- Inflammatix
Compliance, Gastroprotector Therapy
Adherence to Gastro-protection in Non-steroidal Anti-inflammatory Drug (NSAID) Using Patients
Prospective multicentric study to evaluate the compliance of gastroprotective treatment in NSAID patients at risk of GI complications.
- Conditions
- Compliance, Gastroprotector Therapy, Risk Factors
- Trial name
- GADES (NCT00699725)
- Where
- 128 sites in Spain
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis
A Canadian study to evaluate early use of adalimumab after methotrexate failure in early rheumatoid arthritis. The study hypothesis will verify if adalimumab effectively reduces joint damage in more participants when introduced…
- Trial name
- RADAR (NCT01162421)
- Testing
- adalimumab, Methotrexate
- Volunteers
- 77 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ulcerative Colitis
Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis
The primary objective of this study is to evaluate the effect of abrilumab on induction of remission in adults with moderate to severe ulcerative colitis after 8 weeks of treatment as assessed by a total Mayo Score ≤ 2 points…
- Trial name
- NCT01694485
- Testing
- Abrilumab
- Where
- 123 sites in United States, Australia and 18 more
- Volunteers
- 359 people
- Sponsor
- Amgen
Healthy
Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo
The primary and secondary objectives of the current study are the assessments of anti-inflammatory pharmacodynamic effects on segmental endotoxin induced inflammatory response after 4 weeks treatment with BI 1026706.
- Trial name
- NCT02657408
- Testing
- BI 1026706
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Ulcerative Colitis, Digestive System Diseases
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
The purpose of this study is to determine the safety and tolerability of administration of multiple ascending doses of KHK4083 and to select the highest dose tolerated by subjects with moderately active Ulcerative Colitis (UC)…
- Conditions
- Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative, Colitis
- Trial name
- NCT02647866
- Testing
- KHK4083
- Where
- 23 sites in United States, Czechia and 5 more
- Volunteers
- 66 people
- Sponsor
- Kyowa Kirin, Inc.
Colitis, Ulcerative
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial…
- Trial name
- DUET-UC (NCT05242484)
- Testing
- Guselkumab, Golimumab, JNJ-78934804
- Where
- 403 sites in United States, Argentina and 35 more
- Volunteers
- 577 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
The purpose of this study is to prospectively evaluate a scoring system to predict a mild course of disease in patients newly diagnosed with Crohn's disease.
- Trial name
- PROGNOS (NCT02193048)
- Testing
- This study will evaluate a new clinical scoring system in patients receiving routine treatment
- Where
- Germany
- Volunteers
- 216 people
- Sponsor
- Ferring Pharmaceuticals
Gastric Ulcer, Duodenal Ulcer
A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy
The purpose of this study is to study the safety and efficacy of TAK-438, once daily (QD), in participants with a history of gastric or duodenal ulcer requiring long-term NSAID therapy will be investigated.
- Trial name
- NCT01568385
- Testing
- TAK-438
- Where
- 18 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Takeda
Ulcerative Colitis (UC)
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis
A study to investigate the safety, tolerability, and pharmacokinetics (PK) of ONO-6414 orally in healthy adult participants and in patients with active ulcerative colitis (UC).
- Trial name
- NCT07749768
- Testing
- ONO-6414
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Endometriosis
PGL5001 Proof of Concept Study in Inflammatory Endometriosis
This is a prospective, three-part (Part A1, Part A2 and Part B),Phase II study investigating the efficacy, safety, pharmacokinetics and pharmacodynamics of the JNK inhibitor PGL5001 orally administered for up to 5 months with…
- Trial name
- JADE (NCT01630252)
- Testing
- PGL5001
- Where
- Poland
- Volunteers
- 24 people
- Sponsor
- PregLem SA
Chronic Pain, Inflammatory Response
The Effect of Chiropractic Plus Nutritional Supplement in Patients With Chronic Pain and Inflammation.
Evaluating the effect of a combined therapy of chiropractic sessions plus nutritional supplement containing hemp, omega-3 fatty acids, and broccoli extract oil in patients experiencing chronic pain and inflammation.
- Trial name
- NCT05743855
- Testing
- Nutritional Supplement
- Where
- 3 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Standard Process Inc.
Supplementation in Healthy Adults to Assess Impact on Omega 3 Index and Cardiometabolic Health
Change in Omega 3 Index in Healthy Adults With OmeGo or a Standard Omega-3 Oil Supplement
Omega-3 index is used as a proxy for an adequate intake of fish unsaturated fats in the diet. However, omega-3 supplements have not consistently shown the health benefits of eating fresh fish.
- Trial name
- NCT06802068
- Testing
- whole salmon oil, Cod liver oil
- Where
- 2 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Hofseth Biocare ASA
Painful Diabetic Peripheral Neuropathy
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain
This study is to test the effectiveness of pregabalin in treating nerve pain caused by diabetes. The suitable subjects will be patients who also use an non-steroid anti-inflammatory drug for another pain which is not related to…
- Trial name
- NCT01455415
- Testing
- pregabalin
- Where
- 61 sites in United States, Czechia and 2 more
- Volunteers
- 306 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Knee Osteoarthritis
A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)
The study was established to show safety and efficacy of canakinumab and LNA043 in patients with knee osteoarthritis (OA).
- Trial name
- NCT04814368
- Testing
- canakinumab, LNA043
- Where
- 11 sites in United States, Czechia and 4 more
- Volunteers
- 23 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Adult Volunteers, Active Ulcerative Colitis
A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis
This Phase 1b/2a clinical development plan is focused on the use of NP-201 acetate injection to investigate the pharmacokinetics (PK), safety, efficacy, PD (pharmacodynamic) markers (Phase 1b) and tolerability of NP-201 acetate…
- Conditions
- Healthy Adult Volunteers, Active Ulcerative Colitis, Active Ulcerative Colitis (UC)
- Trial name
- NCT06681389
- Testing
- NP-201 acetate injection (Part A)
- Where
- Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- NIBEC Co., Ltd.
Inflammation
An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines
This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete…
- Trial name
- NCT06953518
- Testing
- Qualia Senolytic
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Qualia Life Sciences
Crohn's Disease
Extension Study of Semapimod 60 mg IV x 3 Days
Study CNI-1493-CD06 is an open, single-arm extension studies to CD03 and CD05. CDAI is the only efficacy measure assessed in this study.
- Trial name
- CD06 (NCT00741910)
- Testing
- Semapimod
- Where
- 8 sites in United States, Germany and 2 more
- Volunteers
- 15 people
- Sponsor
- Ferring Pharmaceuticals
Crohn Disease
Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
The purpose of study is to test the effects of an experimental medication GED-0301 (mongersen) in patients who have active Crohn's disease. The study will test GED-0301 compared to placebo for 52 weeks.
- Trial name
- NCT02596893
- Testing
- GED-0301
- Where
- 538 sites in United States, Australia and 33 more
- Volunteers
- 701 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.